First-In-Human [177Lu]Lu-FAPI-XT Therapy Combined With Anti-PD-1 Antibody in a Patient With Metastatic Colon Cancer Who Has Progressed on Multiple Prior Lines of Therapy.
A new radioactive therapy combined with immunotherapy shows initial promise in a resistant cancer, warranting further investigation.
First-in-human administration of [177Lu]Lu-FAPI-XT radiotheranostic therapy combined with anti-PD-1 antibody in a heavily pretreated metastatic colon cancer patient demonstrates initial feasibility of this CAF-targeting radioimmunotherapy combination. This report establishes proof-of-concept for FAP-targeted radioligand therapy as a potential novel treatment modality warranting cohort evaluation.
What the study was
- Study design
- case report (first-in-human)
- Population
- Single patient, heavily pretreated metastatic colon cancer
- Sample size
- 1
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- JCO precision oncology
Why it surfaced
First-in-human novel FAPI radiotheranostic + checkpoint combination; notable mechanistic novelty (CAF-targeting); title-only record — triage_score capped at 3 per schema rule; warrants monitoring for follow-up cohort reports.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.